Update information

Update information

December 2020: We have amended recommendations 1.15.1 and 1.15.4 to bring them in line with the diabetic eye screening programme. The evidence for these recommendations has not been reviewed, and they are marked [2004, amended 2020].

November 2015: We added a note to recommendation 1.7.14, to state that metformin does not have a UK marketing authorisation for the recommended indication. We added a link to the NICE guideline on coeliac disease to recommendation 1.12.1.

September 2015: We added 'that is' to recommendation 1.7.2, to clarify that these regimens should not be offered.

August 2015: We updated and replaced NICE guideline CG15 (published July 2004) for adults and NICE technology appraisal guidance 53 and 60.

Recommendations are marked as [2015], [2004] or [2004, amended 2015]:

  • [2015] indicates that the evidence has been reviewed

  • [2004] indicates that the evidence has not been reviewed since 2004

  • [2004, amended 2015] or [2004, amended 2016] indicates that the evidence has not been reviewed since 2004, but either changes have been made to the recommendation wording that change the meaning or NICE has made editorial changes to the original wording to clarify the action to be taken (see below).

We have also made some changes without an evidence review:

  • Recommendation 1.1.7 had extra information added, to make the recommendation more comprehensive.

  • Recommendation 1.2.5 was amended for clarity, and updated to include some crucial parts of the care plan that were missing from the original recommendation.

  • Recommendations 1.4.10, 1.4.11 and 1.4.13 were updated to remove mention of a low glycaemic index diet, as there is no evidence of benefit for this.

  • Recommendation 1.6.16 was amended to make it clear that self-monitoring skills should be taught as soon as type 1 diabetes is diagnosed.

  • Recommendation 1.6.20 has been amended to remove references to small volumes of blood (which is now normal for all meters) and devices for alternative site monitoring (which are not recommended anyway).

  • Recommendation 1.7.12 was amended to remove a reference to resuspension of insulin, as this is out of date.

  • Recommendation 1.10.10 has been updated to reflect changes in practice for managing hypoglycaemia.

  • Recommendation 1.10.11 has been amended for clarity, and to highlight that glucagon can be given by untrained users in an emergency.

  • Recommendation 1.10.14 has been amended to remove out of date and inconsistent information about different types of insulin.

  • Recommendation 1.12.2 has been updated to remove mention of thyroid disorders, which are now covered in a separate recommendation.

  • Recommendation 1.3.10 has been updated to reflect changes in hypertension management (covered in the NICE guideline on hypertension).

  • Recommendation 1.14.8 has been updated to reflect changes in hospital practice around monitoring systems.

  • Recommendations 1.15.2, 1.15.4 and 1.15.9 were amended to bring them in line with the national diabetes eye screening programme.

  • Recommendations 1.13.2, 1.13.9, 1.15.3 and 1.15.4 have been amended to use the same terminology as the NICE guideline on chronic kidney disease.

  • Recommendation 1.15.23 has been updated to mention postural hypertension, because this is an important sign of autonomic neuropathy.

ISBN: 978-1-4731-1389-3

  • National Institute for Health and Care Excellence (NICE)